Searched for
SANOFI
European pharma chiefs warn region risks losing ground to America, ChinaDrugmakers for months have been warning they could curtail investments and delay the release of new medications in Europe, widening a dispa...- Hyderabad's GCC boom is making its office advantage pricierHyderabad's prime office rents now exceed Bengaluru's, driven by global capability center demand. New-age Grade A+ buildings in Madhapur co...
- Stocks in news: Biocon, Bank of Baroda, TCS, Sanofi India and Tata CapitalIndian equity markets hit a seven-week low on Tuesday, primarily due to escalating crude oil prices and geopolitical instability that swaye...
- Company can face criminal prosecution even if no individual is made accused: Supreme CourtIn a landmark ruling, the Supreme Court has established that companies can be subjected to criminal proceedings even when no individuals ar...
- Supreme Court ruling: Company criminal liability upheld even without director indictment in cheating casesThe Supreme Court ruled criminal cases against companies can proceed without specific individuals named. This decision impacts corporate cr...
- Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump saysNine pharmaceutical firms reached deals with the Trump administration for lower drug prices. These agreements expand the total number of co...
- Warburg set to buy Seacod-maker Universal NutriScience for Rs 2800 croreWill be 4th acquisition for the US private equity giant in India’s healthsector in four months. Kedaara to make 5x rupee returns on exit.
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsA word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...
- JSW Group plans to invest Rs 1.2 lakh crore in Karnataka over 5 years: MB PatilJSW Group plans a significant Rs 1.2 lakh crore investment in Karnataka over five years. The state is also discussing investments with abou...
- Can AI shorten India's rare disease diagnosis journey? New tool aims to do just thatSanofi has launched AccelRare, an AI tool aiding doctors in rare disease pre-diagnosis. This platform generates potential diagnoses within ...
- Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in IndiaIndia's drug regulator has approved Takeda's Qdenga dengue vaccine, the first of its kind. This vaccine is expected to become available in ...
- Merck gets US FDA nod for first-in-its-class oral cholesterol drugThe U.S. FDA has approved Merck's new cholesterol-lowering pill, Lipfendra. This oral medication works by blocking the PCSK9 protein, which...
- Emcure, Sanofi sign distribution pact for oral anti-diabetic products in IndiaEmcure Pharmaceuticals and Sanofi India have announced a distribution agreement. Emcure will promote Sanofi India's oral anti-diabetic prod...
- Sanofi Consumer Healthcare lists on stock exchanges after demerger, shares hit 5% upper circuit on day 1Shares of Sanofi Consumer Healthcare India made their market debut on Friday, listing on both the NSE and BSE. On its first day of trading,...
- Sanofi offers VRS to 800 employees at two units in TelanganaA Sanofi spokesperson told ET that a glut of supplies added during Covid-19 and the struggle to win contracts from Unicef for its critical ...
- Sanofi names Rodolfo Hrosz as India unit headHrosz will transition from being Sanofi’s general manager, Consumer Healthcare business in Brazil to his new role in India as soon as the a...
- Sanofi India skids 2% on poor earnings scorecardSanofi India’s counter fell to a low of Rs 7,159 as against the previous close of Rs 7,280.40 on the National Stock Exchange.
- Sanofi turns to Google in search for better treatmentsSanofi, which made $38.8 billion of sales in 2018, is a major manufacturer of vaccines, insulin, cancer treatments and cardiovascular drugs.
- Genzyme board rejects Sanofi $69-a-share offerBiotech firm Genzyme Corp. says its board of directors is rejecting Sanofi-Aventis SA's $69 a share offer and recommending Genzyme sharehol...
- Sanofi-Aventis likely to buy Genzyme for USD 19 bn: ReportFrench drug maker Sanofi-Aventis is likely to make an formal offer to acquire US-based biotech company Genzyme for USD 19 billion, says a m...
Load More
